drugset / Trial / NCT00291616
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B
Phase 4
Completed
52 enrolled
Seoul National University Hospital
Roche Pharma AG · collabSciClone Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the optimal treatment duration of antiviral therapy for chronic hepatitis B.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Thymalfasin | Peptide | 1.6 mg | Subcutaneous |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |